Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Evaluating Companies

In any case, it s smart to consider each interesting job as one that you hold for the next 30 years. Seen in this light, the problem of objectively evaluating an employer resembles the task of buying stock for the long nm and, at least to some extent, can be approached similarly. By no means is this approach the only one to adopt. [Pg.248]

How many driLgs a company offers is therefore an important factor by which to judge the firm because its business is the riskier, the fewer medicines it makes. [Pg.248]

Patent expirations of best-seiiing dru. Pharmaceutical companies in particular depend on patents to protect their marketed drugs from competition and on both licensing and their own research as sources of drugs new to their pipelines. [Pg.248]

A company that derives much of its revenue from sales of one drug risks a severe loss of income when its primary composition-of-matter patent expires. [Pg.249]

The immediate future of a research-based pharmaceutical company, and therefore its employees prospects, also hangs an the number of drugs it is registering and developing. [Pg.249]


IChemE acknowledges that there is no standard procedure for evaluating chemical reaction hazards (Barton and Rogers, 1997 p. 120). The CSB survey further highlights the variety of approaches to reactive hazard evaluation companies rely to varying degrees on quantitative and qualitative evaluation methods. [Pg.340]

From this present worth evaluation, Company B s bid for baghouse installation should be selected. [Pg.875]

There is little doubt that over the last ten years, environmental reporting has emerged to add a further dimension to the field of evaluating company performance. However, its role in this respect can be enhanced by certain developments, which will be discussed below. [Pg.383]

Among inexperienced chemists who foimd full-time jobs in 1998, there was nearly a 60% chance that any one of them would receive more than one offer of employment (Figime 8-1). These successful job hunters chose between offers, and so will many of you. They and those chemists who received only one offer made a related choice of the companies to which they applied for work. Obviously, this latter choice faces every job seeker, so each must adopt standards for judging employers. Evaluating companies to find ones where you would like to work is as important as looking into colleges to attend, cars to buy, or investments to make. [Pg.245]

There are four main uses of injury statistics (1) to identify high-risk jobs or work areas, (2) to evaluate company health and safety performance, (3) to evaluate the effectiveness of hazard-abatement approaches, and (4) to identify factors related to illness and injiuy causation. An illness and injuryreporting and analysis system requires that detailed information must be collected about the characteristics of illness and injuries and their frequency and severity. The Occupational Safety and Health Act (1970) established iUness and injury reporting and recording requirements that are mandatory for aU employers, with certain exclusions such as small establishments and government agencies. Regulations have been developed to define how employers are to adhere to these requirements (BLS 1978). [Pg.1173]

Approximately 70% of evaluated companies store a dangerous substance classified as toxic or highly toxic. In approximately 25% of evaluated companies, the toxic substances are treated in such an amoimt and in such a physical form (gas, liquefied gas and highly volatile hquid) to be considered as possible threat for human health in the vicinity of the evaluated source of risk. Figure 2 shows the percentage occurrence of the use of individual software and methods in which acute toxicity limits are used. The versions of modeling software were not distinguished in the evaluation, because they were not always stated in risk analysis documents. The most often used software include TEREX (T-Soft 2000), SAVE II, ROZEX (TLP 2001), EFFECTS (TNO 2003), ALOHA (US ERA 2007) and CEI method (AIChE 1994). [Pg.886]


See other pages where Evaluating Companies is mentioned: [Pg.314]    [Pg.447]    [Pg.2241]    [Pg.525]    [Pg.245]    [Pg.246]    [Pg.247]    [Pg.248]    [Pg.248]    [Pg.249]    [Pg.250]    [Pg.252]    [Pg.253]    [Pg.254]    [Pg.255]    [Pg.256]    [Pg.257]    [Pg.258]    [Pg.259]    [Pg.260]    [Pg.262]    [Pg.263]    [Pg.264]    [Pg.265]    [Pg.266]    [Pg.267]    [Pg.268]    [Pg.269]    [Pg.270]    [Pg.271]    [Pg.272]    [Pg.274]    [Pg.275]    [Pg.276]    [Pg.278]    [Pg.392]    [Pg.21]    [Pg.45]    [Pg.50]   


SEARCH



Company strategies for designing non-clinical safety evaluation

Criteria for evaluating companies

Evaluating Companies and Job Offers

Evaluating the company

Pharmaceutical companies safety evaluation

© 2024 chempedia.info